(via NewsDirect)
Lehr said two patients have achieved a confirmed partial response among the first 12 patients enrolled in the trial evaluating the potential of ONA-XR in combination with anastrozole to treat hormone receptor-positive metastatic endometrial cancer.
The findings are encouraging as ONA-XR exhibits initial signals of clinical activity and confirmed tumor shrinkage, Lehr added.
Contact Details
+1 347-449-0879
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source